ClinicalTrials.gg
RecruitingNCT07939061URIS-1Updated Nov 16, 2026

Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder

An interventional study of Active peroneal transcutaneous neuromodulation (URIS I, Stimvia) and Sham peroneal transcutaneous neuromodulation (URIS I, Stimvia) in Overactive Bladder and Daytime Urinary Incontinence, sponsored by General University Hospital, Prague. Recruiting at 1 site in Czechia. Open to participants aged 7 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by General University Hospital, Prague · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
7 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Urinary Bladder, Overactive with a site in Czechia — 3 open to participants now, 3 under way, none of them phase 3. Urinary Bladder, Overactive · Czechia.

Planned enrollment
32nd of 34
47 · median 596
Started
2026
with 1 other
No phase
3 of 39
1 open now
Registered
39th of 39
by date
Lead sponsor
1 of 39
General University Hospital, Prague

Among the 39 studies in Urinary Bladder, Overactive with a site in Czechia, this one is the 32nd largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 with no phase, and was the 39th registered.

Urinary Bladder, Overactive

859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

3 of the 39 studies in Urinary Bladder, Overactive with a site in Czechia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 74 Urinary Bladder, Overactive studies recruiting now, 44 (59%) set no upper age limit and 16 (22%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 7 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Urinary Bladder, Overactive with a site in Czechia, or all of them as a file.
02

Study summary

This prospective, randomized, sham-controlled clinical investigation evaluates the efficacy and safety of peroneal transcutaneous electrical neuromodulation (URIS I system) in children aged 7-12 years with wet overactive bladder and daytime urinary incontinence who did not respond or responded insufficiently to standard urotherapy. Participants are randomized 1:1 to active or sham stimulation and receive 12 weekly bilateral sessions of 30 minutes over 12 weeks.

Read the detailed description

Investigator-initiated academic study sponsored by the General University Hospital in Prague. The primary objective is to determine the effect of peroneal transcutaneous electrical neuromodulation on the frequency of daytime urinary incontinence in children with overactive bladder. The primary variable is the clinical responder rate at the end of treatment (week 12). Secondary objectives are the effect on micturition frequency, functional bladder capacity, parent- and child-reported symptoms and quality of life (DVISS, PIN-Q, PGI-I), clinician-rated global improvement (CGI-I), and the safety, tolerability and adherence to treatment.

Children are randomized 1:1 (permuted blocks, sealed opaque envelopes) to active stimulation or sham stimulation with the stimulation voltage set to 0 V. Both procedures are identical in preparation, electrode placement, duration and the 4 Hz acoustic signal; the child and the parent are separated from the lower limbs by an opaque screen. Planned sample size: 21 evaluable participants per arm; 47 participants are to be enrolled to allow for approximately 10% attrition.

The URIS I device is supplied by the manufacturer, Stimvia s.r.o., under a loan agreement. The manufacturer is not a sponsor or collaborator of this study.

03

Conditions studied

  • Overactive Bladder
  • Daytime Urinary Incontinence

Keywords

  • Pediatric overactive bladder
  • Peroneal nerve stimulation
  • Transcutaneous electrical neuromodulation
  • Urotherapy-refractory
04

Who can participate

Ages eligible
7 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 7 to 12 years, boys and girls
  • Wet form of overactive bladder (urgency with daytime urinary incontinence, with or without nocturnal enuresis)
  • At least 8 wet days during waking hours in 2 weeks, based on the wetting diary
  • No or insufficient response to standard urotherapy (ICCS) lasting at least 3 months
  • Ability and willingness of the child and the parent to follow the protocol; signed

Exclusion criteria

Exclusion Criteria:

  • Severe daytime incontinence (complete wetting in more than 50% of episodes)
  • Anticholinergic treatment for overactive bladder in the last 3 months
  • Neurogenic lower urinary tract dysfunction
  • Congenital malformations of the lower urinary tract (e.g. bladder exstrophy, anorectal malformation)
  • Severe systemic or neurological disease (e.g. cardiac disorders, epilepsy)
  • Local lesions of the lower limbs (skin disease, osteosynthesis material)
  • Peripheral neuropathy of the lower limbs
  • Presence of an electronic implant in the body (e.g., a neurostimulator)
  • Functional constipation during the previous 3 months (Rome III-IV criteria)
  • Symptomatic urinary tract infection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
47 participants (estimated)

Study arms

  • Experimental
    Active stimulation

    Active bilateral peroneal transcutaneous neuromodulation with URIS I, 30 minutes, once a week for 12 weeks.

    Device: Active peroneal transcutaneous neuromodulation (URIS I, Stimvia)

  • Sham comparator
    Sham stimulation

    Sham stimulation with URIS I at 0 V (no stimulation delivered), same procedure, electrode placement, 4 Hz acoustic signal and schedule as the active arm: 30 minutes, once a week for 12 weeks.

    Device: Sham peroneal transcutaneous neuromodulation (URIS I, Stimvia)

Interventions

  • DeviceActive peroneal transcutaneous neuromodulation (URIS I, Stimvia)

    Bilateral peroneal transcutaneous electrical neuromodulation with the URIS I system. A neutral self-adhesive electrode is placed on the lower abdomen; the optimal stimulation point at the lateral edge of the popliteal fossa is identified by a rhythmic motor response of the leg, and the stimulation voltage is set to the lowest value that evokes this response. Stimulation lasts 30 minutes, once a week for 12 weeks (12 sessions). The device emits a 4 Hz acoustic signal.

  • DeviceSham peroneal transcutaneous neuromodulation (URIS I, Stimvia)

    Identical preparation, electrode placement and duration as active stimulation, but the stimulation voltage is set to 0 V bilaterally so that no stimulation is delivered. Exposure to active stimulation is limited to the minimum needed to locate the stimulation point. 30 minutes, once a week for 12 weeks (12 sessions). The device emits the same 4 Hz acoustic signal.

06

What researchers measure

Primary outcomes

  1. Proportion of clinical responders at the end of treatment

    A clinical responder is a child who meets either or both of the following criteria at the end of treatment: 1. a reduction of at least 50% in the number of wet days during waking hours over 14 days of the wetting diary compared with baseline; 2. a PGI-I score of 2 or less rated by both the parent and the child. PGI-I (Patient Global Impression of Improvement) ranges from 1 = very much better to 7 = very much worse.

    Time frame: Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)

Secondary outcomes

  1. Change in the number of daytime incontinence episodes per 24 hours

    Number of incontinence episodes during waking hours per 24 hours, averaged over 14 days of the wetting diary; change from baseline.

    Time frame: Baseline, Week 6, Week 12

  2. Change in the severity of daytime incontinence episodes

    Severity of incontinence episodes (complete vs. partial wetting) per 24 hours during waking hours over 14 days of the wetting diary; change from baseline.

    Time frame: Baseline, Week 6, Week 12

  3. Change in the number of wet days

    Number of wet days during waking hours over 2 weeks (a wet day is a day with leakage producing a stain on underwear larger than a 10 CZK coin / 1 EUR coin); change from baseline.

    Time frame: Baseline, Week 6, Week 12

  4. Change in micturition frequency and functional bladder capacity

    Mean number of voids per 24 hours and mean voided volume (functional bladder capacity) from the 48-hour frequency-volume chart; change from baseline.

    Time frame: Baseline, Week 6, Week 12

  5. Change in DVISS total score (parent-rated)

    Dysfunctional Voiding and Incontinence Symptom Score total score completed by the parent; change from baseline. Higher scores indicate more severe symptoms.

    Time frame: Baseline, Week 6, Week 12

  6. Change in Bower PIN-Q total score (child-rated)

    Pediatric Incontinence Questionnaire (PIN-Q) total score completed by the child as a measure of quality of life; change from baseline.

    Time frame: Baseline, Week 6, Week 12

  7. PGI-I score rated by the child and by the parent

    Patient Global Impression of Improvement, rated separately by the child and by the parent (1 = very much better to 7 = very much worse).

    Time frame: Week 6, Week 12

  8. CGI-I score rated by the unblinded investigator

    Clinical Global Impression of Improvement rated by the principal investigator or co-investigator (1 = very much improved to 7 = very much worse).

    Time frame: Week 6, Week 12

  9. Number, type and severity of treatment-related adverse events

    Adverse events (description, severity, onset, resolution, action taken and relationship to neuromodulation) recorded at every stimulation session and visit.

    Time frame: From the first stimulation to Week 12

  10. Adherence to treatment

    Proportion of participants who attend at least 80% of the 12 planned stimulation sessions.

    Time frame: Week 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared to protect patient privacy, as this study evaluates a vulnerable pediatric population and is subject to strict GDPR and institutional data protection regulations.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2028, 20 months after the start.

Of 134 non-industry interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 20 months is close to that.

Counting every sponsor, half of 175 studies reached it within 19 months; a quarter within 10 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartActual
Sep 3, 2026
Primary completionEst.
Jun 1, 2028
CompletionEst.
Jun 1, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939061
Lead sponsor
General University Hospital, Prague
Responsible party
Zuzana Jirásková (Pediatric urologist, Department of Urology, First Faculty of Medicine, Charles University and General University Hospital, Prague, General University Hospital, Prague) — Principal investigator
First posted
Nov 16, 2026
Start date
Sep 3, 2026
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Zuzana Jiraskova, MD, FEAPU
Contact
zuzana.jiraskova@vfn.cz
+420 224 967 859
Petra Novakova, MD
Contact
petra.novakova@vfn.cz
+420 224 967 859
Zuzana Jiraskova, MD, FEAPU
principal investigator · General University Hospital, Prague

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion